These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33720614)

  • 1. [Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria].
    Sturov NV; Popov SV; Mamporia NK; Mager AA
    Ter Arkh; 2020 Dec; 92(11):106-109. PubMed ID: 33720614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes.
    Arakaki RF
    Postgrad Med; 2016 May; 128(4):409-17. PubMed ID: 26982554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
    Geerlings S; Fonseca V; Castro-Diaz D; List J; Parikh S
    Diabetes Res Clin Pract; 2014 Mar; 103(3):373-81. PubMed ID: 24529566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of sodium-glucose cotransporter-2 inhibitors-induced glucosuria in the incidence of urogenital infection on postmenopausal women with diabetes.
    Marques LPJ; Mendonça NA; Müller L; André ACPD; Madeira EPQ; Vieira LMSF
    Postgrad Med; 2020 Nov; 132(8):697-701. PubMed ID: 33016178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
    Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
    Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of sodium-glucose cotransporter 2 inhibitor-related genital and urinary tract infections via electronic medical record-based common data model.
    Ko S; Kim H; Shinn J; Byeon SJ; Choi JH; Kim HS
    J Clin Pharm Ther; 2021 Aug; 46(4):975-983. PubMed ID: 33565150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
    Raskin P
    Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse Events of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease: A Retrospective Chart Review.
    Choi H; Nguyen LA; Wan J; Milani H; McGill K; Park J
    Perm J; 2021 May; 25():. PubMed ID: 33970086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium-dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: An observational study.
    Tada K; Gosho M
    Fundam Clin Pharmacol; 2022 Dec; 36(6):1106-1114. PubMed ID: 35484899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus.
    Kashiwagi A; Maegawa H
    J Diabetes Investig; 2017 Jul; 8(4):416-427. PubMed ID: 28178390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: a new approach to an old problem.
    Jabbour SA
    Postgrad Med; 2014 Jan; 126(1):111-7. PubMed ID: 24393758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus.
    Nair S; Wilding JP
    J Clin Endocrinol Metab; 2010 Jan; 95(1):34-42. PubMed ID: 19892839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sodium-Glucose Cotransporter 2 Inhibitors and Urinary Tract Infection: Is There Room for Real Concern?
    Wiegley N; So PN
    Kidney360; 2022 Nov; 3(11):1991-1993. PubMed ID: 36514393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
    Liu B; Wang Y; Zhang Y; Yan B
    Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent.
    Nomura S
    Curr Top Med Chem; 2010; 10(4):411-8. PubMed ID: 20180760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors.
    Rizzi M; Trevisan R
    Nutr Metab Cardiovasc Dis; 2016 Nov; 26(11):963-970. PubMed ID: 27514605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [NON-CARDIAL EFFECTS OF SGLT2 INHIBITORS (REVIEW)].
    Doroshkevych I; Vozniuk L; Voloshchuk N; Klekot O; Kyrychenko O
    Georgian Med News; 2018 Dec; (285):57-62. PubMed ID: 30702071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to fight obesity with antidiabetic drugs: targeting gut or kidney?
    Baretić M; Troskot R
    Minerva Endocrinol; 2015 Mar; 40(1):71-83. PubMed ID: 25366984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium glucose-linked transport protein 2 inhibitors: An overview of genitourinary and perioperative implications.
    Chandrashekar M; Philip S; Nesbitt A; Joshi A; Perera M
    Int J Urol; 2021 Oct; 28(10):984-990. PubMed ID: 34155680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.